Schedule

iMyoS

Co-Chairs: Chet Oddis (USA); Annet Royen-Kerkhof (the Netherlands) Therapeutic Targeting of Immunopathogenic Pathways in Myositis Femke van Wijk (Utrecht University, Netherlands) and David Fiorentino (Stanford, USA) Geographic Differences in Treatment of MA-ILD: North American vs. Asian Perspective North American Perspective Erin Wilfong (Vanderbilt Univ. Medical Center, USA) Asian Perspective Takahisa Gono (Nippon Medial School, Japan) Advances in Exercise Therapy in Response to the Advances in Medical Management Susan Maillard (Great Ormond Street Hospital, UK) Selected Oral Presentations O-7 Clustering Analysis of Immune Cell Subsets and Clinical Phenotypes in the Idiopathic Inflammatory Myopathies Yuhui Li (Peking University Health Science Center, China) O-8 Thromboembolism Risk Associated with Intravenous Immune Globulin Use in Patients with Idiopathic Inflammatory Myopathy: A National Database Study Didem Saygin (University of Pittsburgh, USA)

Plenary

Immune Reset: Achieving Remission with CD19-CAR T Cell Therapy Moderator: David J. Chang MD, MPH (Chief Medical Officer, Cabaletta Bio) The Next Frontier for CAR T Cells: Autoimmune Diseases Carl H. June MD (Richard W. Vague Professor in Immunotherapy, Professor of Medicine, Director, Center for Cellular Immunotherapies, Director, Parker Institute for Cancer Immunotherapy, University of Pennsylvania Perelman School of Medicine, USA) The Myositis Opportunity: B Cells & CD19-CAR T Cell Therapy Rohit Aggarwal MD, MS (Professor of Medicine, University of Pittsburgh School of Medicine, Co-Director, UPMC Myositis Center, Program Director, UPMC Myositis Fellowship Program, USA) Cabaletta Bio: Realizing the CAR T Potential in Myositis & Beyond David J. Chang MD, MPH (Chief Medical Officer, Cabaletta Bio)

Cabaletta

Co-Chairs: Lucy Wedderburn (UK); Christian Lood (USA) State of Art Review on Biomarkers and Novel Therapeutics for Juvenile Myositis Hanna Kim (NIH, USA) Intersection of IFN and Mitochondrial Changes in Juvenile Myositis Meredyth Wilkinson (University College London, UK) Sodium Thiosulfate for Treatment of Calcinosis in Dermatomyositis: Trial Results Adam Schiffenbauer (NIH, USA) Selected Oral Presentations O-9 Interferon-driven Dynamics: Disease Trajectories and in vitro Insights in Juvenile Dermatomyositis Saskia Veldkamp (University of Utrecht, Netherlands) O-10 Juvenile Scleromyositis Overlap Patients Demonstrate a Unique Peripheral Blood Immunophenotype Using Bulk RNA Sequencing Amanda Robinson (University of Utah, USA)

Plenary

Moderator: Manuel Lubinus (USA) Panelists: Karen Cheng (PM/IMNM), Martha Arnold (IBM), Rodney Jansen (IBM), Ingrid de Groot (DM), Benita Moyers (MDA5), Silke Schlüter (Overlap Myositis)

Patient Support Organizations

Co-chairs: Lisa Rider (USA); Julie Paik (USA) Evaluating ILD as a Key Outcome in IIM Trials Sonye Danoff (Johns Hopkins, USA) Skin Endpoints/Outcomes in Clinical Trials Victoria Werth (University of Pennsylvania, USA) Adaptive Clinical Trials - The REMAP-CAP Experience Bryan McVerry (University of Pittsburgh, USA) Issues and Challenges in Clinical Trial Design Rohit Aggarwal (University of Pittsburgh, USA)

Plenary

O-11 Study of the Muscle Damage During Anti-Synthetase Syndrome Through Spatial Transcriptomics: Involvement of Type II IFN and Macrophages in B Lymphocyte Survival Linda Chenane (Inserm, France) O-12 Impaired Force Generating Capacity by Single Skeletal Muscle Fibers from Immune-mediated Necrotizing Myopathy Patients Tom Kerkhoff (Amsterdam University Medical Center, Netherlands)

Plenary

Break

1A: Pathology Workshop Anthony Amato (Brigham & Women’s Hospital, USA) Anne Schänzer (Justus-Leibig Universität, Germany) Alan Pestronk (Washington University in St. Louis, USA) Ichizo Nishino (National Institute of Neuroscience, Japan) David Lacomis (University of Pittsburgh, USA) This session will review topics relevant to different histopathologic subtypes of myositis, standardization of IHC protocols, impact of biopsy method on histopathologic analyses, and inter-rater reliability of histopathology interpretation.

Workshop

1B: Disease Models Workshop Human Skeletal Muscle Model of Juvenile Dermatomyositis Lauren Covert (Duke University, USA) Antibody Mediated HMGCoA Reductase Model Olivier Boyer (CHU Rouen Normandie, France) Cell Mediated TIF1g Model Naoko Okiyama (Tokyo Medical and Dental University, Japan) Session highlights will include discussion of both in vitro and in vivo model systems that can help to advance our knowledge of myositis immunopathogenesis.

Workshop